G1 Therapeutics Inc (GTHX)

G1 Therapeutics (GTHX) Stock Price & Analysis


GTHX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.08 - $8.40
Previous Close$2
Average Volume (3M)553.88K
Market Cap
Enterprise Value$65.26M
Total Cash (Recent Filing)$94.35M
Total Debt (Recent Filing)$55.92M
Price to Earnings (P/E)-1.4
Feb 21, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding51,843,669
10 Day Avg. Volume613,820
30 Day Avg. Volume553,879
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)2.41
Price to Sales (P/S)2.02
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit1.27
Enterprise Value/Ebitda-1.86
Price Target Upside350.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3



Ownership Overview

9.72% Mutual Funds
8.19% Other Institutional Investors
82.09% Public Companies and
Individual Investors


What was G1 Therapeutics Inc’s price range in the past 12 months?
G1 Therapeutics Inc lowest stock price was $1.08 and its highest was $8.40 in the past 12 months.
    What is G1 Therapeutics Inc’s market cap?
    Currently, no data Available
    When is G1 Therapeutics Inc’s upcoming earnings report date?
    G1 Therapeutics Inc’s upcoming earnings report date is Feb 21, 2024 which is in 79 days.
      How were G1 Therapeutics Inc’s earnings last quarter?
      G1 Therapeutics Inc released its earnings results on Nov 01, 2023. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.341 by -$0.009.
        Is G1 Therapeutics Inc overvalued?
        According to Wall Street analysts G1 Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does G1 Therapeutics Inc pay dividends?
          G1 Therapeutics Inc does not currently pay dividends.
          What is G1 Therapeutics Inc’s EPS estimate?
          G1 Therapeutics Inc’s EPS estimate is -$0.27.
            How many shares outstanding does G1 Therapeutics Inc have?
            G1 Therapeutics Inc has 51,843,670 shares outstanding.
              What happened to G1 Therapeutics Inc’s price movement after its last earnings report?
              G1 Therapeutics Inc reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.341. Following the earnings report the stock price went down -18.788%.
                Which hedge fund is a major shareholder of G1 Therapeutics Inc?
                Among the largest hedge funds holding G1 Therapeutics Inc’s share is Fisher Asset Management LLC. It holds G1 Therapeutics Inc’s shares valued at N/A.


                  Company Description

                  G1 Therapeutics Inc

                  G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.


                  Top 5 ETFs holding GTHX

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold GTHX. The ETFs are listed according to market value of GTHX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Sangamo Biosciences
                  Crispr Therapeutics AG
                  Bluebird Bio

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis